Compare Alphabet Inc Class A (GOOGL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GOOGL trades at $350.50, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats. Recent news highlights AI-driven growth opportunities through partnerships with Anthropic and SpaceX, while YouTube's subscription price increases signal revenue diversification. Analyst consensus remains overwhelmingly positive with 87% buy ratings.

Outlook remains favorable given strong fundamentals and AI leadership, though regulatory risks and market volatility present challenges. The $431.83 consensus price target implies 23% upside potential. Investment opportunity centers on sustained AI monetization and cloud growth, balanced against antitrust scrutiny and competitive pressures in digital advertising.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.